Snapiti - we all know about the other commercially available biomarkers. Draw your own conclusions but I wouldn't get too distraught.
Printable View
I wouldn't actually compare the IT sector with the biotech(molecular diagnostic) sector, they both have squiggly lines and the syllable 'tech' though.
CS explained that they see their customers as the insurers rather than the patients or urologists, so the key reporting metrics may be any of those, but he did also though in response to a question raised obligate to consider more frequent updates.
I wouldn't object to quarterly reports also actually, but at the end of the day I'm ok with companies with good fundamental propositions that just get on with business too. Quarterly reports may just attract more short term speculators, we've seen enough of them come and go this year already.
I would say they really quite confident in their NZ$100M target, in fact they just told their target was over that.
Thanks for reporting back MAC. Swans comment about the Insurer's being their Customer reinforces my take of things. If it is covered , it will sell.
CMS will likely influence this. When they announce coverage, this thing will rock. Be in or be left behind...
No no . come back!
Seriously, how do you see sales progressing without Insurance coverage?
Just take time to look back on recent posts and no one has the foggiest clue where the Company is going,when it's going to get there and if it does,how long it's going to take.There is a chance it's going to succeed but it's about as certain as Argentina beating someone in rugby...IMHO..
Absolutely,
They have set a modest numerical financial target, have already built a lab to match that capacity, they have raised all the capital they need to fund that growth, they have completed clinical trials and regulatory approvals, they have a first mover advantage, a disruptive technology, several clinical value propositions over the incumbent technology, they offer a one third reduction in costs to their customers (insurers), the market (respectful cancer patients) is growing each year, they have a time saving product in a market with an ever increasing shortage of urologists, and they have a marketing strategy that appears well considered.
Yes, I'm a content shareholder of Pacific Edge, whilst I recognise we are in the early days of the launch and the trajectory is a difficult estimation, I have some confidence in their position and greater business plan and in a lot more research in the background.
And, we have a positive a set of affirmations from the company today;
“Sufficient funds in place for planned development and growth strategy in existing markets”
“As at 31 March 2014, cash and equivalents of $20.4 million and no debt”
“Expect revenue to grow as we expand our footprint in the US”
“Expand our sales presence in the United States and drive ambitious revenue target”
“Target gross revenues of over NZ$100 million after five full years of trading with very attractive margins”
Chairmans address at ASM in 2009
We have a very clear strategy for significant growth over the next 5 years
in two very broad directions. In both those wide marketplaces significant growth and change is beginning........
We will see the beginnings of this trend in this financial year; but the lead-times from testing, approving and specifying our products hit the market, can take up to 3 years. Consequently we will only see the beginnings of the revenue growth in this fiscal year and much more in the next fiscal year.
Whoops, wrong thread. Sorry there is no similarity between chips for GPS and test tubes. My apologies